Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer.

Trial Profile

Randomized Phase II Study of Weekly Irinotecan/Carboplatin (ICb) With or Without Cetuximab (Erbitux) in Patients With Metastatic Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Carboplatin (Primary) ; Cetuximab (Primary) ; Irinotecan (Primary)
  • Indications Advanced breast cancer; Male breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Sep 2016 Planned End Date changed from 1 Dec 2014 to 1 Dec 2016.
    • 27 Sep 2015 Results (n=1) presented at the ASCO - Breast Cancer Symposium 2015
    • 08 Jun 2011 Planned end date (Jun 2013) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top